VIPERA: Viral Intra-Patient Evolution Reporting and Analysis

Author:

Álvarez-Herrera Miguel1ORCID,Sevilla Jordi1,Ruiz-Rodriguez Paula1ORCID,Vergara Andrea23,Vila Jordi23,Cano-Jiménez Pablo4ORCID,González-Candelas Fernando15,Comas Iñaki45ORCID,Coscollá Mireia1

Affiliation:

1. Institute for Integrative Systems Biology (I2SysBio, University of Valencia—CSIC), FISABIO Joint Research Unit ‘Infection and Public Health’ , C/Agustín Escardino, 9, Paterna 46980, Spain

2. Department of Clinical Microbiology, CDB, Hospital Clínic of Barcelona; University of Barcelona; ISGlobal , C. de Villarroel, 170, Barcelona 08007, Spain

3. CIBER of Infectious Diseases (CIBERINFEC) , Av. Monforte de Lemos, 3-5, Madrid 28029, Spain

4. Institute of Biomedicine of Valencia (IBV-CSIC) , C/ Jaime Roig, 11, Valencia 46010, Spain

5. CIBER of Epidemiology and Public Health (CIBERESP) , Av. Monforte de Lemos, 3-5, Madrid 28029, Spain

Abstract

Abstract Viral mutations within patients nurture the adaptive potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during chronic infections, which are a potential source of variants of concern. However, there is no integrated framework for the evolutionary analysis of intra-patient SARS-CoV-2 serial samples. Herein, we describe Viral Intra-Patient Evolution Reporting and Analysis (VIPERA), a new software that integrates the evaluation of the intra-patient ancestry of SARS-CoV-2 sequences with the analysis of evolutionary trajectories of serial sequences from the same viral infection. We have validated it using positive and negative control datasets and have successfully applied it to a new case, which revealed population dynamics and evidence of adaptive evolution. VIPERA is available under a free software license at https://github.com/PathoGenOmics-Lab/VIPERA.

Funder

European Research Council

Ministerio de Ciencia e Innovación

Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España

European Commission

Generalitat Valenciana

Publisher

Oxford University Press (OUP)

Reference70 articles.

1. Rilpivirine Inhibits SARS-CoV-2 Protein Targets: A Potential Multi-target Drug;Ameen;Journal of Infection and Public Health,2021

2. Freyja: Depth-weighted De-Mixing;Andersen Laboratory,2023

3. ARTIC-ncov2019: ARTIC Nanopore Protocol for nCoV2019 Novel Coronavirus;ARTICnetwork,2023

4. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing;Benjamini;Journal of the Royal Statistical Society: Series B (Methodological),1995

5. Mutational Induction in SARS-CoV-2 Major Lineages by Experimental Exposure to Neutralising Sera;Brandolini;Scientific Reports,2022

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3